EVALUATION OF THE EFFECTIVENESS OF BIOMARKERS IN THE EARLY DETECTION OF ANGIOPOLYNEUROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
Abstract
References
1. Tesfaye, S., & Selvarajah, D. (2012). Advances in the Epidemiology, Pathogenesis and Management of Diabetic Peripheral Neuropathy. Diabetes/Metabolism Research and Reviews, 28(S1), 8–14.
2. Ziegler, D., & Fonseca, V. (2006). From Pathogenesis to Treatment of Diabetic Polyneuropathy. Diabetes/Metabolism Research and Reviews, 22(6), 423–428.
3. Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O’Brien, P. C., & Melton, L. J. (1993). The Prevalence by Staged Severity of Various Types of Diabetic Neuropathy, Retinopathy, and Nephropathy in a Population-Based Cohort: The Rochester Diabetic Neuropathy Study. Neurology, 43(4), 817–824.
4. Callaghan, B. C., Xia, R., Reynolds, E. R., Banerjee, M., & Feldman, E. L. (2015). Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurology, 72(12), 1468–1476.
